Haemonetics (HAE) News Today

Haemonetics Corporation (NYSE: HAE) shares have increased sharply after CSL Plasma expanded its planned use of Haemonetics’ plasma-collection technology across its U.S. network. The announcement improves the company’s longer-term revenue outlook, although valuation concerns and mixed analyst commentary may be limiting further gains.

• Positive Sentiment: CSL rollout expands the addressable opportunity: CSL Plasma plans to deploy Haemonetics’ NexSys PCS devices, Persona PLUS technology and related disposables across more than 300 existing U.S. plasma centers, with completion targeted by the end of 2027. Investors view the broader deployment as a potential source of recurring equipment and consumables revenue. Haemonetics Soars 12% on CSL Update
• Positive Sentiment: Analysts raise their expectations: Barrington increased its price target to $140 from $118 while maintaining an Outperform rating. BTIG also previously lifted its target to $130, reinforcing the view that the CSL agreement could support future growth. Barrington Adjusts Price Target on Haemonetics
• Positive Sentiment: Operating performance remains supportive: Recent company updates cited fiscal fourth-quarter revenue of $346.4 million, adjusted EPS of $1.29, organic revenue growth and fiscal 2027 guidance for reported revenue growth of 4% to 7%. A $100 million share repurchase also supported investor sentiment. Haemonetics jumps after strong Q4 results
• Neutral Sentiment: Momentum has pushed the stock near record levels: Haemonetics reached a new 52-week high following the CSL announcement. The move increases visibility but also raises the bar for further earnings and contract-related upside. Haemonetics Stock Hits 52-Week High
• Negative Sentiment: Valuation concerns remain: A Seeking Alpha analysis downgraded Haemonetics, arguing that the CSL agreement improves the outlook but does not provide an attractive entry point after the recent rally. Zacks likewise cautioned that recent earnings-estimate revisions may not support continued near-term momentum. Haemonetics: CSL Improves the Outlook, Not the Entry Point